spacer
home > ebr > summer 2019 > adc characterisation
PUBLICATIONS
European Biopharmaceutical Review

ADC Characterisation

The biopharmaceutical industry is experiencing unprecedented growth that is primarily driven by the development and implementation of monoclonal antibody (mAb)-based therapeutics. mAbs have been shown as promising therapeutics for the treatment of a variety of lifethreatening diseases, particularly cancer (1). More than 40 therapeutic mAbs have been approved for treatment, and hundreds more are currently under development. One class of therapeutic mAbs that serve as potential chemotherapeutic agents is antibody-drug conjugates (ADCs). Several ADCs have received market approval, mainly for oncology treatment. The potential of ADCs is due to the ability of the antibody to target specific cells, which leads to lower toxicity of the drug and therefore increases drug dosage levels that are safer than chemotherapeutic agents. The development of ADCs is challenging. In this article, the analytical techniques currently used to determine the drug-to-antibody ratios (DARs), their limitations, and potential novel combinations of characterisation techniques are explored.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Christopher M Bianchetti PhD is a Research Scientist in the method development and validation group at PPD® Laboratories, where he is responsible for providing technical guidance on scientific method development and validation projects and troubleshooting instruments, methods, and procedures. Christopher has more than 12 years of experience in protein production, purification, and the biochemical and biophysical characterisation of macromolecules (proteins, nucleic acids, and polysaccharides). Previously, he led an independent research group that designed and implemented high-throughput biochemical methods to screen enzymes for novel carbohydrate degrading activity.

Henry J Parker is an Associate Scientist in the biopharma method development and validation group at PPD Laboratories, where he is responsible for designing, developing, and validating scientific methods for the analysis of biopharmaceutical products. Henry has more than three years’ experience in the biochemical and biophysical characterisation of macromolecules using techniques such as high-performance liquid chromatography and capillary electrophoresis.

Katherine C Hanson PhD is the Lab Manager for the biopharma method development and validation group at PPD Laboratories. Katherine has more than five years of experience in development and validation of GMP-compliant analytical methods for a wide range of compounds, including enzymes, antibodies, and viral gene therapies. Previously, she was a Protein Engineer focused on determining mechanism of action for molecular motors.

Stephen Gacheru PhD serves as the Vice President of biopharmaceutical product development for PPD Laboratories, where he oversees analytical testing for large molecules. Stephen has more than 20 years’ experience working in the biologics field. He has extensive global experience in protein characterisation, validations, and regulatory submissions. He also has expertise in outsourcing to CMOs and CROs, working with clients and developing successful customer supply relationships.
spacer
Christopher M Bianchetti PhD
spacer
spacer
spacer
Henry J Parker
spacer
spacer
spacer
Katherine C Hanson PhD
spacer
spacer
spacer
Stephen Gacheru PhD
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Francine Lane Recipient of 2019 DIA Global Inspire Award

JERSEY CITY – March 21, 2019 – Francine Lane, TrialScope Vice President of Global Transparency, has received a 2019 Global Inspire Award from the Drug Information Association (DIA). Lane, chair of the DIA’s Clinical Trial Disclosure Community, and Robert Paarlberg, past chair, are co-recipients of the Community Engagement Award. The award recognizes DIA community chairs for consistently driving engagement while advancing knowledge and thought leadership within their membership communities.
More info >>

White Papers

Bringing more control to temperature-sensitive logistics

UPS Supply Chain Solutions

By 2016, world sales of cold-chain drugs and biologics such as vaccines and blood plasma products will near $240 billion1. The increase has led to a surge in discussion about how to protect these products throughout the transportation logistics cycle. Industry experts are recommending that the term “cold chain” be eliminated from rules, guidance and best-practice documents. “Cold chain” now includes a broader spectrum of temperature ranges, such as controlled room temperature (CRT). This white paper focuses on the initial steps required to establish a temperature-sensitive supply chain.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement